Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes

Diabetes Care

Volumn 35, Issue 11, 2012, Pages 2198-2200

  Mudaliar, Sunder ^a,b   Armstrong, Debra A ^a   Mavian, Annie A ^b   O'Connor Semmes, Robin ^c   Mydlow, Patricia K ^c   Ye, June ^c   Hussey, Elizabeth K ^c   Nunez, Derek J ^c   Henry, Robert R ^a,b   Dobbins, Robert L ^c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PLACEBO; REMOGLIFLOZIN ETABONATE;

ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREND STUDY;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PYRAZOLES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84868095962     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0508     Document Type: Article

References (9)

1. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609:148-154
2. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affi nity Na +/glucose cotransporter SGLT2. Delineation of themajor renal reabsorptivemechanism for D-glucose. J Clin Invest 1994;93:397-404
3. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 1992;263:F459-F465
4. You G, Lee WS, Barros EJ, et al. Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 1995;270:29365-29371
5. Dobbins RL, O'Connor-Semmes R, Kapur A, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012;14:15-22
6. Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012;14:601-607
7. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657
8. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-1031
9. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies.DiabetesObesMetab 2007;9:799-812 (Pubitemid 47555203)